Synchronous Parotid and Thyroid Gland Metastases from Breast Cancer

Yasemin B. Cihan
Kemal Deniz
Mehmet S. Yilmaz

Department of Radiation Oncology, Kayseri Training and Research Hospital, Kayseri, Turkey
Department of Pathology, Erciyes University Hospital, Kayseri, Turkey
Department of Radiology, Kayseri Training and Research Hospital, Kayseri, Turkey

Keywords
Breast neoplasm · Metastasis · Parotid · Thyroid · Synchronous neoplasms

Summary
Background: Metastases to the parotid and thyroid glands from breast cancer are rare and have a poor prognosis. Case Report: We present the case of a patient with breast carcinoma and synchronous involvement of both the parotid and thyroid gland, and review the literature on this subject. Conclusion: Metastatic malignancy in clinically suspect thyroid and parotid nodules could be detected more frequently with routine use of fine needle aspiration biopsy.

Introduction
Metastasis to the head and neck region, including the parotid and thyroid glands (PTG), are rare. Besides, metastases from distant sites to the PTG can present diagnostic problems and lead to management dilemmas [1, 2]. In clinical series, renal, lung, and breast carcinomas are frequent sources of PTG metastasis [3, 4]. The incidence of such metastases differs from primary lesions depending on the type of material analyzed. Immunohistochemical staining of tissue sections has improved the differential diagnosis in these lesions. Fine needle aspiration (FNA) and histopathology of tru-cut biopsies can be important tools in establishing the correct diagnosis, and also allow the distinction between potential primary tumors [3]. Here, we present a case of PTG swelling in a female patient with known breast cancer. Relevant histopathological and immunohistochemical features of breast cancer metastasis to the PTG will be discussed.

Case Report
In 2005, a 70-year-old woman presented with a left-sided breast lump. Excisional biopsy showed a ductal carcinoma. Radical mastectomy was performed. Pathology showed a grade II, invasive ductal carcinoma pT2 (3 × 2.5 cm) with N3 (12/16) metastatic spread to the axillary lymph nodes. Estrogen and progesterone receptors were strongly positive (+++), and C-erbB 2 was negative in the immunohistochemical analysis. Post-operatively, the patient received 6 cycles of adjuvant chemotherapy. Later, the patient was treated with a 5-week course of radiotherapy (50 Gy/2 fractions) and was started on anastrozole.

Eighteen months later, the patient complained of a swelling and pain in the left parotid gland region, which had persisted for the last 2 months. There was no history of fever, and no correlation between the swelling and food ingestion. On examination, a solitary diffuse swelling of approximately 2 × 2 cm was present on the left side of the parotid region. The swelling was firm, non-tender, and fixed to underlying structures. There was no focal nerve palsy. A neck computed tomography (CT) and ultrasound examination showed a node of 2 cm in the parotid gland, hypodense multiple nodes in the thyroid gland, and 2 suspicious ipsilateral neck lymphadenopathies (fig. 1A). Her complete hematological findings...
biochemical profile, and chest radiograph were normal. Cancer antigen (CA) 15–3 was high, carcinoembryonic antigen (CEA) was normal. Metastasis to the thyroid and parotid gland was confirmed by FNA cytology (fig. 2 A).

A combination of total thyroidectomy and parotidectomy with elective neck dissection was recommended but the patient refused. A superficial lobe parotidectomy was performed (fig. 1B). Microscopical analysis of the parotid gland showed ductal adenocarcinoma of the breast metastatic to the superficial lobe of the parotid gland, cytological features consistent with metastases from breast cancer (fig. 2 B). Immunohistochemical examination indicated a negative result for C-erbB2. However, strong staining was observed with estrogen (fig. 2 C). Postoperatively, whole-neck external beam irradiation at a dose of 50 Gy/25 fraction/5 week using 6 MV photons was given to the patient. She was also investigated for other sites for metastatic disease. A whole-body bone scan showed bone metastases, and abdominal ultrasound revealed liver involvement. The patient was treated with 8 cycles of paclitaxel 80 mg/m² once a week, followed by radiotherapy. Later, she refused treatment and was lost to follow-up.

**Discussion**

Metastases to the PTG rarely arise from cutaneous sites of the head and neck but predominantly from infracavicular tumors. Most metastases migrate through either the lymphatics or the blood stream, except for the parotid gland [1–3]. The average survival after diagnosis is 6–9 months. There are individual differences in the metastatic spread of neoplasms to the PTG, which are very important for therapeutic and prognostic reasons [3–6].

Signs and symptoms of metastatic tumors are similar to those of primary tumors. Most clinical metastases in the PTG present as solitary nodules. Most thyroid and parotid metastases are discovered during routine follow-up physical examinations or imaging studies after resection of the primary tumor [1–5]. In our case, the patient presented with a palpable mass. She had undergone a mastectomy 18 months earlier, and the parotid and thyroid mass was the first presenting symptom.

**Fig. 1.** A Computed tomography scan revealing enhancing masses in the thyroid gland; B CT scan revealing a superficial lobe parotidectomy.

**Fig. 2.** A Malignant tumor infiltrating the thyroid acini (S stained; ×400); B Section showing ductal adenocarcinoma of the breast metastatic to the superficial lobe of the parotid gland (H and E; ×40); C Immunohistochemistry for estrogen showing strong positivity on metastatic cells to the parotid gland (E; ×40).
Metastatic disease involving the PTG may be a diagnostic problem. It may be evident upon palpation, ultrasonography, Doppler ultrasonography, CT or magnetic resonance imaging, and visible in the histopathological examination. In general, however, in metastatic PTG swelling, an FNA could accurately confirm a clinical suspicion of metastasis with low morbidity [4–6]. In the present case, the metastatic lesion was diagnosed by FNA cytology, supported by a biopsy from the breast.

Although the optimal therapy sequence is unknown, treatment of PTG metastatic disease is a combination of surgical removal of solitary tumors, chemotherapy, and radiation therapy [2, 6, 7]. Our patient refused the recommended surgical treatment plan and was treated with a superficial lobe parotidectomy, followed by adjuvant radiotherapy and chemotherapy.

Estrogen and progesterone receptor determination is helpful in defining the primary tumor [7]. In our case, histologic sections from a mastectomy specimen and an excisional biopsy from the parotid gland mass were compared. We compared findings of hematoxylin-eosin and various immunohistochemical stains, also of the parotid gland after parotidectomy. The comparison showed the immunohistochemical features were very important to make an accurate diagnosis as in our case [7].

Almost all current therapeutic modalities for metastasis to the PTG in the presence of disseminated disease are palliative. Current immunohistochemical markers have improved the distinction between a number of potential primary tumors. Accordingly, the diagnosis of metastatic breast carcinoma may require histochemical and immunohistochemical as well as clinical information. In any patient with a previous history of malignancy, a new thyroid and/or parotid mass should be considered as a metastasis until proven otherwise.

Disclosure Statement

None of the authors have a substantial direct or indirect commercial financial incentive associated with the publication of the article. There is no source of extra-institutional funding for this study.

References